0001213900-23-020741.txt : 20230317 0001213900-23-020741.hdr.sgml : 20230317 20230317060901 ACCESSION NUMBER: 0001213900-23-020741 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better For You Wellness, Inc. CENTRAL INDEX KEY: 0001852707 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-56262 FILM NUMBER: 23740626 BUSINESS ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 BUSINESS PHONE: 6143689898 MAIL ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 FORMER COMPANY: FORMER CONFORMED NAME: Fast Track Solutions, Inc. DATE OF NAME CHANGE: 20210322 10-Q/A 1 f10q0522a1_better.htm AMENDMENT NO. 1 TO FORM 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

(Mark One)

 

 QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: May 31, 2022

 

or

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                     to                   

 

Commission File Number:            000-56262              

 

BETTER FOR YOU WELLNESS, INC.

 

(Exact name of registrant as specified in its charter)

 

nevada   87-2903933
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

c/o Ian James

1349 East Broad Street

Columbus, OH 43205

 

(Address of Principal Executive Offices) (Zip Code)

 

(614) 368-9898

 

(Registrant’s Telephone Number, Including Area Code)

 

N/A

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐

Non-accelerated Filer

 

  Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of March 17, 2023  there were 404,014,987 shares of Common Stock and 700,000 shares of Series A Preferred Stock issued and outstanding.

 

 

 

 

 

 

EXPLANATORY NOTE

 

Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2022 (the “Original Form 10-Q”).

 

Background of Restatement

 

This Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed August 9, 2022, the negative net loss was reported as $1,373,066 for the three months ended May 31, 2022. The Amended and Restated negative net loss is reported as $ 891,872 a difference of $481,194 less in net loss for the three month period  ended May 31, 2022.

 

In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.

 

Internal Control Considerations

 

In connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.

 

Items Amended in this Amendment No. 1

 

This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended:

 

Part I, Item 1, Financial Statements
   
Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations
   
Part I, Item 4, Controls and Procedures
   
Part II, Item 1A, Risk Factors

 

Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.

 

Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement.

 

 

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Amendment No. 1 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact, included in this Amendment No. 1 regarding development of our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:

 

any statements of the plans, strategies and objectives of management for future operations;
   
any statements concerning proposed new products, services or developments;
   
any statements regarding future economic conditions or performance;
   
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
   
our estimates regarding the sufficiency of our cash resources and our need for additional funding; and,
   
any statement that our business, financial condition and results of operations may be materially adversely affected by global health epidemics, including the recent COVID-19 pandemic.

 

The words “believe,” “anticipate,” “design,” “estimate,” “plan,” “predict,” “seek,” “expect,” “intend,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. We cannot guarantee that we actually will achieve the plans, intentions or expectations expressed in our forward-looking statements and you should not place undue reliance on these statements. There are a number of important factors that could cause our actual results to differ materially from those indicated or implied by forward-looking statements. These factors and the other cautionary statements made in this Amendment No. 1 should be read as being applicable to all related forward-looking statements whenever they appear herein. Except as required by law, we do not assume any obligation to update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 

 

INDEX

 

    Page 
PART I - FINANCIAL INFORMATION  
   
ITEM 1 FINANCIAL STATEMENTS - UNAUDITED 1
  CONSOLIDATED Balance Sheets - UNAUDITED 1
  CONSOLIDATED Statements of Operations- UNAUDITED 2
  STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - UNAUDITED  3
  CONSOLIDATED Statement of Cash Flows - unaudited 4
  Notes to Financial Statements - unaudited 5
     
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 18
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 29
ITEM 4 CONTROLS AND PROCEDURES 29
 
PART II - OTHER INFORMATION  
 
ITEM 1 LEGAL PROCEEDINGS 31
ITEM 1A RISK FACTORS 31
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 31
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 31
ITEM 4 MINE SAFETY DISCLOSURES 31
ITEM 5 OTHER INFORMATION 31
ITEM 6 EXHIBITS 31
   
SIGNATURES 32

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Better For You Wellness, Inc.

Condensed Consolidated Balance Sheet (unaudited)

As of May 31, 2022 and February 28, 2022

 

   Consolidated May 31,
2022
   February 28,
2022
 
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents  $3,309   $9,642 
Inventory   7,037    
-
 
Prepaids and other assets   78,072    
-
 
Total Current assets   88,418    9,642 
Equipment, net   2,129    
-
 
Goodwill    583,586    
-
 
TOTAL ASSETS  $674,133   $9,642 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current Liabilities          
Accounts Payable  $161,815   $375,408 
Deferred Compensation   100,160    
-
 
Clearbanc Debit Card   2,288    
-
 
Related Party Notes Payable   35,000    
-
 
Total Current Liabilities  $299,263   $375,408 
           
Long-Term Liabilities          
Notes Payable - PayPal Capital   2,335    
-
 
Notes Payable Shopify Capital   483    
-
 
Convertible notes payable, net accumulated interest   254,369    
-
 
TOTAL LIABILITIES  $556,449   $375,408 
           
Stockholders’ Equity (Deficit)          
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022)  $70   $70 
Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042 issued and outstanding as of May 31, 2022 and February 28, 2022, respectively)   38,012    37,075 
Additional paid-in capital   2,609,749    1,485,364 
Shares cancellable   
-
    (250,000)
Accumulated deficit   (2,530,147)   (1,638,275)
Total Stockholders’ Equity (Deficit)   117,684    (365,766)
           
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)  $674,133   $9,642 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

Better For You Wellness, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

For the three months ended May 31, 2022 and 2021

 

   Three Months
May 31,
2022
   Three Months
May 31,
2021
 
Revenue        
Merchandise Sales  $306   $- 
Cost of Goods Sold   6,069    - 
Gross Profit   (5,763)   - 
           
Operating Expenses:          
Share-based expense   684,050    - 
Selling, General and Administrative   196,995    72,051 
Total operating expenses   881,045    72,051 
           
Operating Income/(Loss)   (886,808)   (72,051)
           
Other Income/(Expense)          
Other income   
-
    - 
Interest expense   (5,063)   
-
 
Other expense   
-
    - 
Total other expense   (5,063)     
           
Net income/(loss)  $(891,872)  $(72,051)
           
Basic and Diluted net loss per common share
  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding - Basic and Diluted
   363,657,794    140,868,130 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

Better For You Wellness, Inc.

Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit)

For the Three Months Ended March 31, 2022 and 2021 (Unaudited)

 

 

   Common
Shares
   Par
Value
Common
Shares
   Series A
Preferred
Shares
   Par
Value
Series A
Preferred
Shares
   Additional
Paid-in-Capital
   Shares
Cancellable
   Accumulated
Deficit
   Total 
                                 
Balances, February 28, 2022   370,747,042   $37,075    700,000   $70   $1,485,364   $(250,000)  $(1,638,275)  $(365,766)
Common shares cancelled and returned to the Company   
(7,048,873
)   (705)   
-
    
          -
    (249,295)   250,000    
-
    
-
 
Common shares issued for shares payable   
325,000
    33    
-
    
-
    (33)   
-
    
-
    
-
 
Common shares issued for services to Company   5,085,000    509    
-
    
-
    272,226    
-
    
-
    272,735 
Common shares issued for purchase of subsidiary   11,000,000    1,100    
-
    
-
    548,900    
-
    
-
    550,000 
Stock option expense   -    
-
    -    
-
    411,315    
-
    
-
    411,315 
Warrants Issued   -    
-
    -    
-
    78,072    
-
    
-
    78,072 
Warrants Issued                       13,514              13,514 
Debt Forgiveness   -    -    -    -    49,686    
-
    -    49,686 
Net loss   -    -    -    -    
-
    
-
    (891,872)   (891,872)
Balances, May 31, 2022   380,108,169   $38,012    700,000   $70   $2,609,749   $
-
   $(2,530,147)  $117,684 

 

   Common Shares   Par Value Common Shares   Series A Preferred Shares   Par Value Series A Preferred Shares   Additional Paid-in Capital   Accumulated Deficit   Total 
                                    
Balances, February 28, 2021   -   $
-
    
-
    
    -
   $1,185   $(4,935)  $(3,750)
Common shares issued after reorganization   359,996,332    36,000    -    -    (36,000)   -    - 
Series A preferred shares issued after reorganization   
-
    
-
    700,000    700    69,930    
-
    70,000 
Expenses paid on behalf of the Company and contributed to capital   -    -    -    -    3,951    -    3,951 
Net loss   -    -    -    -    -    (72,051)   (72,051)
Balances, May 31, 2021   359,996,332   $36,000    700,000   $700   $39,067   $(76,986)  $(1,850)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3

 

 

Better For You Wellness, Inc.

Consolidated Statement of Cash Flows

 

   Three Months
May 31,
2022
   Three Months
May 31,
2021
 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(891,872)  $(72,051)
Adjustment to reconcile net loss to net cash used in operating activities:          
Share based expenses   684,050    70,000 
Amortized debt discount and debt issuance costs   12,139    
-
 
Depreciation   194    
-
 
Changes in current assets and liabilities:          
Inventory   6,060    
-
 
Accounts Payable   (213,593)   (1,900)
Accrued Interest   5,063    
-
 
Deferred Compensation   100,160    
-
 
Other liabilities   (6,403)   - 
Net cash used in Operating Activities   (304,202)   (3,951)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Fixed Asset   (2,323)   
-
 
Net cash used in Investing Activities   (2,323)   
-
 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Payment of debt issuance Cost   (28,320)   
-
 
Proceeds from Convertible loan, net of original issue discount   279,000    
-
 
Proceed from related party note payable   
-
    - 
Notes Payable – LT   (174)   - 
Noncontrolling interest   
-
    - 
Expenses contributed to capital   49,686    3,951 
Net cash provided by financing activities   300,192    3,951 
           
Net change in cash  $(6,333)  $- 
           
Beginning cash balance  $9,642   $- 
Ending cash balance  $3,309   $- 
           
NON-CASH FINANCING TRANSACTIONS:          
Discount on notes payable for warrants  $13,514   $
-
 
Warrants issued and extended for common stock issuance costs  $78,072   $
-
 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

Better For You Wellness, Inc.

Notes to Unaudited Consolidated Financial Statements

 

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

5

 

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.

 

6

 

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).

 

Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

 

7

 

 

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three months ended May 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022 and February 28, 2021, the Company had no deferred revenues.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 was $3,309 and $9,642, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

8

 

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and 2021. Thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation - Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

9

 

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

 

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

10

 

 

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   537 
Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   May 31,
2022
   May 31,
2021
 
Total revenues  $6,974   $19,455 
Net (loss) income  $(891,872)  $(90,902)
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

   For the
three months  ended
May 31,
   For the
three months   ended
May 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $   6,974   $19,455 
Net income  $(8,281)  $(9,425)

 

11

 

 

Note 5 - Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

12

 

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.

 

Note 7 - Convertible Note Payable

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

Note 8 - Stock Purchase Warrant Liability

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA. The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.

 

13

 

 

Note 9 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May 31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May 31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $15,000.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

14

 

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totalling $68,000.

 

On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $15,468.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $550,000.

 

During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totalling approximately $40,248.

 

Shares Cancellable

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.

 

On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been cancelled and returned to the Company.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 6,500,000 fully vested on May 31, 2022. The remaining 13,500,000 shares vest over the next 2 years. During the three months ended May 31, 2023, no shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.

 

The Company fair valued the options on the grant at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $411,315. The total unamortized stock option expense at May 31, 2022 was approximately $2,151,622.

 

Additional Paid-In Capital

 

During the quarterly period ended May 31, 2022, a total of $2,609,749 posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including negative $249,295 for the termination of the Williamsburg Venture Holdings’ Equity Purchase Agreement, a negative $33 due to a clerical error, the common shares related to these Subscription Agreements were not issued until Q1 of 2022, $411,315 of share option vestment/expense for the Board of Directors, $272,226 for Mast Hill, $548,900 for purchase of Mango Moi Subsidiary/No subsidiary acquired this quarterly filing, and $78,072 in Warrants issued related to MacRab, 13,514 in Warrants related to JH Darbie finder’s agreement and debt treatment of Mast Hill, and $49,686 in debt forgiveness of accrued expense payable to Green Ohio Ventures.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $6,441 during the year ended February 28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totalling $500.

 

15

 

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $1,185 during the year ended February 28, 2021.

 

The $8,126 in total payments made by the former directors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

 

Note 10 - Related-Party Transactions

 

Loan to Company

 

During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totalling approximately $2,323 and the Company made payments to Green Ohio Ventures, LLC, totalling approximately $96,079, which resulted in Green Ohio Ventures being owed approximately $0 for loans made to the Company.

 

These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary.

 

Note 11 – Goodwill

 

In the previous filing, the Company reported an Impairment Expense of $577,473. In recategorization  of the Company’s financials to meet GAAP standards, the Company removed the Impairment Expense related to the Company’s purchase of Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The revised financials now reflect Goodwill in the amount of $583,586.

 

While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three months ended May 31, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred. 

 

Note 12 - Subsequent Events

 

On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

16

 

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.

 

The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

 

17

 

 

ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

 

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

Company Overview

 

Business Overview

 

We are a sustainable brands and services company headquartered in Columbus, Ohio. We are evaluating opportunities targeting six goals-based wellness categories within the rapidly growing wellness industry to create a leading global wellness conglomerate.

 

Through our dual buy and build model, we evaluate the wellness industry in the following six goals-based categories:

 

Better Health

 

Better Fitness

 

Better Nutrition

 

Better Appearance

 

Better Sleep

 

Better Mindfulness

 

As an early-stage company, our Company generated $306 and $19,455 in revenue for the three months ended May 31, 2022 and 2021 respectively. Our strategy is designed to offer wellness consumers a diverse synergistic portfolio of brands and products that will allow them to live a life of intention and improve their quality of life. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois. As a fledgling brand, Mango Moi, LLC lacked capital, access to capital, and other resources necessary to scale and maintain its growth trajectory. We believe that as a result of Mango Moi, LLC’s lack of resources, our Company was presented with an attractive acquisition opportunity and that our Company’s resources would allow Mango Moi, LLC to expand.

 

18

 

 

We believe wellness consumers purchase with intention and specifically seek out the brands and products that improve their quality of life. Furthermore, we believe wellness consumers pursue these six goals-based dimensions of wellness and are positioning the Company to capitalize on this demand. With skin being a human’s largest organ, we have initially prioritized skincare and haircare to help wellness consumers look and feel better with clean and natural products. We intend to expand into additional wellness categories with functional foods, beverages, supplements, and more.

 

Our management team brings deep expertise in heavily regulated industries, operating, brand identity, genetics, and services, and raising capital to the public market. We seek synergistic and complementary mergers and acquisition opportunities, implementing operational efficiencies to eliminate duplicative measures and centralize administrative operations to achieve more significant revenues and profitability. Additionally, we expect to leverage our network of retail relationships, as well as acquire and manage brands and services cultivated in the beauty and wellness industry to secure sales in major retailers in the United States and globally.

 

Our management team monitors a variety of trends and factors that follow, which could impact our operating performance.

 

As an early-stage company, the Company has relatively few transactions to date.

 

Trends and Other Factors Affecting Our Operating Performance

 

Our management team monitors various trends and factors that could impact our operating performance.

 

Revenue Strategy

 

Our revenue growth strategy follows a dual buy and build model in which we acquire brands and related infrastructure and develop brands and related infrastructure in-house. In addition to scaling the Company’s wholly-owned subsidiary, Glow Market LLC, which currently owns and operates our Better Suds soap brand, we have executed multiple non-binding letters of intent to acquire companies within the skincare sector, including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions is dependent on numerous factors, including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois.

 

Market Opportunity

 

We aim to become a major participant in the $1.5 trillion global wellness industry. We believe our innovative wellness-related offerings converge with wellness consumer trends and demands for “Better-For-You” brands and products that can satisfy all pricing points. We expect consumer trends towards adoption of these healthier lifestyles to continue.

 

Competition

 

We will compete with companies that operate in the plant-based and science-focused wellness market. Many of our competitors will have substantially greater financial resources, broader market presence, longer-standing relationships with distributors, retailers, and suppliers, longer operating histories, more extensive production and distribution capabilities, more robust brand recognition, more significant marketing resources, and more comprehensive product lines than us. We believe that principal competitive factors in this category include, among others, quality ingredients, wellness profile, cost, convenience, branding, and marketing.

 

19

 

 

Sales and Marketing Costs

 

As we continue to grow our “BFYW” product portfolio, we expect to expand our sales and marketing team by adding dedicated personnel to service additional retail customers. Outside sales representatives and brokers may be added to expand our sales efforts. We further envision engaging, developing and possibly acquiring a subscription box retail operation. Marketing expenditures are expected to begin primarily online and in product fees (as we engage retail store expansion), as well as other similar in-store marketing costs. These expenses will be categorized as net deductions to revenue under GAAP instead of marketing expenses. We plan to hire a national marketing firm to implement digital video and display campaigns, connected television, social media, and search engine marketing. As we expand and grow revenue, we will build a brand management team (to support Management, who oversees all “BFYW” marketing efforts) to focus on digital marketing, social media, and other marketing functions.

 

Operating Costs

 

Our operating costs include raw materials, labor and related benefits, manufacturing overhead, marketing, sales, distribution, shipping, and other general and administrative expenses. We attempt to manage the impact of our operating costs through fixed hourly rate agreements with legal counsel and certain consultants.

 

Fluctuations in Costs

 

Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs, and our productivity efforts. If we are unable to manage cost fluctuations through pricing actions, cost savings projects, sourcing decisions, and consistent productivity improvements, it may adversely impact our gross margin, operating margin, and net earnings. Sales can also be adversely impacted following pricing actions if there is a negative impact on the consumption of our products. We strive to implement, achieve, and sustain cost improvement plans, including supply chain optimization, general overhead and workforce optimization, as well as outsourcing projects as deemed appropriate.

 

Commodities

 

In the future, our profitability could depend on our ability to anticipate and react to raw material costs, among other things. Raw materials can be sourced from various parts of the globe, and the prices of raw goods are subject to many factors beyond our control. These factors include variables in world economic conditions, political events, tariffs, trade wars or other events.

 

Acquisitions

 

The Company follows a dual buy and build business model for growth through acquisitions and in-house development of brands. We have executed multiple non-binding letters of intent to acquire companies within the skincare sector including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions is dependent on numerous factors including but not limited to satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance.

 

Strategic Advisory Committee

 

To assist in the expansion of the Company, management sought and received unanimous consent of the Board of Directors to create and seat a Strategic Advisory Committee composed of respected industry leaders who bring relevant experience, networks, and leadership to the Company’s various initiatives.

 

20

 

 

Discussion of Financial Statement

 

As an Early-Stage Company with few transactions, the Company’s expenditures were heavily Selling, General, and Administrative (“SG&A”). The Company engaged Carter, Ledyard, & Milburn LLP and Anthony L.G., PLLC as legal counsel, to be consulted on a case-by-case basis as may be necessary for corporate legal services and securities counsel. Payroll expenses, including deferred compensation, were the single largest category of cash expenditures for the quarter. Pursuant to their Employment Agreements, Ian James, Stephen Letourneau and Jacob Ellman have deferred compensation. Accordingly, the following represents each individual’s deferred compensation since March 1, 2022: Ian James has deferred $49,799, Stephen Letourneau has deferred $38,197, and Jacob Ellman has deferred $12,164. Both Mr. James and Mr. Letourneau have stipulated that they will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing.

 

The Company’s SG&A further includes the cost of EDGAR and news release filing services, payroll of a single person, website development and publishing, professional services such as accounting, SRAX for regular updates of NOBO data for the shareholder lists for ongoing shareholder communications, Governmental filing fees including business licensing.

 

Systems and Controls

 

As an early-stage company, the Company has very few transactions to date. The Company’s Board of Directors consists of 7 members, 5 of which are non-executive independent directors. The Board of Directors’ reviews transactions, and the CEO signs off on transactions. The Company is developing revenue recognition processes and procedures for the business, including revenue streams, point of performance obligation discharged, etc., to comply with applicable State, Federal, and International Laws and Regulations.

 

Critical Accounting Policies and Estimates

 

We prepare our consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Pursuant to Note 2 - Summary of Significant Accounting Policies, the consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues.

 

Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.  

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

21

 

 

COVID-19

 

An outbreak of infectious respiratory illness caused by a novel coronavirus known as COVID-19 spread globally in 2020. This outbreak resulted in travel restrictions, closed international borders, enhanced health screenings at ports of entry and elsewhere, disruption of and delays in healthcare service preparation and delivery, prolonged quarantines, cancellations, supply chain disruptions, lower consumer demand, layoffs, defaults, and other significant economic impacts, as well as general concern and uncertainty.

 

The pandemic has not materially impacted our operations in 2021 nor 2022 thus far.

 

Financial Statements and Exhibits

 

The Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination. The Company’s business purpose is to seek the acquisition of or merger with an existing company.

 

The Company is an “emerging growth company” (“EGC”), that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (the JOBS Act), that eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commissions (SEC’s) reporting and disclosure rules (See Emerging Growth Companies Section Below).

 

The Company has elected February 28th as its fiscal year-end.

 

Results of Operations

 

The following table sets forth selected items in our consolidated financial data in dollar amounts and as a percentage of revenue for the period represented:

 

   For the
three months
   For the
three months
 
   Ended
May 31,
2022
   Ended
May 31,
2021
 
         
Revenues   306    - 
Cost of Goods   6,069    - 
Gross Profit and Gross Margin   (5,763)   - 
Operating Expenses   881,045    72,051 
Net (Loss) Income   (891,872)   (72,051)

 

Revenues

 

The company generated $306 and $0 for the three months ended May 31, 2022, and 2021 respectively, an increase of $306. The increase was due to merchandise sales. The Company’s current business plan is to explore and evaluate various business opportunities in the plant-based food, beverage, and consumer packaged goods (“CPG”) sectors, including but not limited to mergers, acquisitions, or business combination transactions.

 

Cost of Goods Sold

 

We recorded $6,069 and $0 for Cost of Goods Sold for the three-months ended May 31, 2022, and 2021 respectively, an increase of $6,069. The increase in Cost of Goods Sold was due to increased product development of inventory.

 

22

 

 

Gross Profit and Gross Margin

 

We recorded a negative $5,763 and $0 in Gross Profit for the three months ended May 31, 2022, and 2021 respectively, a decrease of $5,763. We recorded a lower Gross Profit for the three months that ended May 31, 2022, compared to the first quarter of the prior year due to an increase in the Cost of Goods and a decrease in merchandise sales due to a decrease in marketing.

 

Operating Expenses

 

We recorded $881,045 and $72,051 in Operating Expenses for the three months ended May 31, 2022, and 2021 respectively. We incurred substantially higher Operating Expenses for the three months ended May 31, 2022, compared to the prior year’s first quarter due to contemplated acquisition transactions, legal fees, due diligence costs, accounting, travel, and consultants. The primary reason for the increase in operating expenses is an increase of approximately $684,050 in share-based expenses and approximately $196,995 in general and administrative expenses.

 

Income Taxes

 

We file a consolidated federal income tax return with our subsidiaries. The provision for income taxes is computed by applying statutory rates to income before taxes.

 

Deferred income taxes are recognized for the tax consequences in future years of temporary differences between the financial reporting and tax bases of assets and liabilities as of each period-end based on enacted tax laws and statutory rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A 100% valuation allowance has been established on deferred tax assets for the period ending May 31, 2022, and February 28, 2022, due to the uncertainty of our ability to realize future taxable income.

 

We account for uncertainty in income taxes in our financial statements as required under ASC 740, “Income Taxes.” The standard prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also guides de-recognition, classification, interest, and penalties, accounting in interim periods, and disclosure and transition accounting. Management determined we took no material uncertain positions in our tax returns.

 

Net (Loss) Income

 

We recorded a loss of $891,872 and $72,051 for the three months ended May 31, 2022, and 2021, respectively. We recorded a substantially higher net loss for our three months ended May 31, 2022, compared to the first quarter in the prior year due to the factors discussed above.

 

Liquidity and Capital Resources

 

Our cash balance at May 31, 2022, and 2021 was $3,309 and $2,708, respectively. We raised a total of $250,680 in net proceeds from Mast Hill, LLC in convertible debt in the three months that ended May 31, 2022. We are presently reliant on capital contributions towards expenses from Mr. Ian James, the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors. Mr. James has not guaranteed that he will continue to support our capital needs. Therefore, we may not have the ability to continue as a going concern. In order to implement our plan of operations for the next twelve-month period, we may require further funding. Being a start-up stage company, we have very limited operating history. After a twelve-month period, we may need additional financing but currently do not have any arrangements for such financing.

 

If we need additional cash and cannot raise it, we will either have to suspend operations until our Company raises the necessary financing or cease operations entirely.

 

23

 

 

Corporate History

 

Better For You Wellness, Inc. (“we”, “us”, “our”, the “Company” or the “Registrant”), was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On January 28, 2021, as a result of an Application for Custodianship granted by the Eighth Judicial District Court, Clark County, Nevada, styled as “In the matter of Sauer Energy, Inc., a Nevada corporation, Case Number: A-20-826848-P”, Jeffrey DeNunzio was appointed Custodian of Sauer Energy, Inc. (the “Predecessor”).

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230, and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Jeffrey DeNunzio was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor, and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021 at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until trading under the new ticker symbol “FTRK” for the Company began on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

On May 5, 2021, after the completion of the Reorganization, we canceled all of the stock we held in Sauer Energy, Inc. resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

On July 19, 2021, Fast Track Solutions entered into a Share Purchase Agreement by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021, CRS sold 700,000 shares of the Fast Track Solutions’ Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of Fast Track Solutions; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000). The consummation of the transactions contemplated by this Share Purchase Agreement resulted in a change in control of Fast Track Solutions, with Ian James, Stephen Letourneau and GOHV becoming the largest controlling stockholders.

 

Cumulatively, Ian James and Stephen Letourneau retained a majority of the membership interests (collectively constituting approximately 84.12%) of GOVH.

 

24

 

 

On July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer. In addition, Mr. DeNunzio resigned as Director on July 30, 2021. Mr. Ian James was also appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors, and Mr. Stephen Letourneau was appointed Director. The resignation of Mr. DeNunzio was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On August 18, 2021, a Certificate of Amendment to change our name to “Better For You Wellness, Inc.” was filed with the Nevada Secretary of State.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 17, 2021, we entered into “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, we entered into an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

On September 17, 2021, we entered into another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On September 17, 2021, Mr. David H. Deming was appointed Secretary of the Company’s Board of Directors.

 

On September 17, 2021, we engaged Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis as may be necessary. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel to be important to the growth of the Company going forward.

 

On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock is 08771B105.

 

On October 1, 2021, our Board of Directors unanimously approved the establishment of an Audit Committee and appointed Montel Williams, David Deming, and Joseph Watson to the newly formed Audit Committee. Our Board of Directors also unanimously approved the establishment of a Compensation Committee and appointed Leslie Bumgarner, Montel Williams, and Joseph Watson to the newly formed Compensation Committee.

 

25

 

 

On November 18, 2021, Ms. Leslie Bumgarner advised the Company’s Board of Directors that she would resign as a director and Compensation Committee member of the Company effective upon December 31, 2021. The resignation of Ms. Bumgarner was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group. The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s Common Stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH. Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act. The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only registrable securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement, and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement). The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

On December 6, 2021, we announced that the Company had formed a wholly-owned subsidiary, Glow Market LLC, an Ohio Limited Liability Company, to build and operate digitally-native, mission-driven brands within the clean beauty sector in multiple consumer product categories. Glow Market LLC, launched its first brand, Better Suds, an impact-driven brand that sells cruelty-free natural soap. Better Suds is committed to positively impacting the environment by removing 1 pound of plastic from the ocean for every soap sold through donations to Ocean Blue Project Inc., a 501(c)(3) organization that removes plastics from oceans and waterways. With the Company’s launch of Glow Market LLC, we ceased to be a shell company, as defined in Rule 12b-2 under the Exchange Act, and are no longer a blank-check company.

 

On December 9, 2021, we announced that the Company had submitted an application to the OTC Markets Group to up-list its common stock for trading on the OTC Markets Venture Market, or the OTCQB, and pending the completion of the application process and its acceptance by the OTC Markets Group, the Company expects that its common stock will begin trading on the OTCQB under the Company’s current ticker symbol “BFYW”.

 

On December 14, 2021, we appointed Christina Jefferson to the Board as an Independent Director, effective January 1, 2022, in order to replace Leslie Bumgarner whose resignation became effective December 31, 2021.

 

26

 

 

On December 15, 2021, we reported on a phased fundraising of up to $1,000,000 USD in a Private Placement of restricted Common Stock to investors who qualify as “accredited investors”.

 

On February 2, 2022, we received approval from OTC Markets Group to up-list our common stock for trading to the OTC Markets Venture Market, or the OTCQB, as of February 3, 2022 under the Company’s current ticker symbol “BFYW”.

 

On February 5, 2022, our Board of Directors unanimously approved the Establishment of a Strategic Advisory Committee tasked with providing acceleration, reach and guidance to further enhance the Company’s value proposition and portfolio. Our Board of Directors appointed six initial Committee Members by unanimous consent including: David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous consent of the five non-executive independent members of our Board of Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, Christina Jefferson was appointed to the Company’s Compensation Committee filling the vacancy left by former director Leslie Bumgarner, and Joseph Watson was appointed as Chairperson of the Company’s Compensation Committee.

 

On February 11, 2022, we entered into a non-binding Letter of Intent with Amanda Cayemitte, Yapo M’Be, and Mango Moi, LLC setting forth the contemplated terms for a transaction in which the Company would acquire 100% ownership interest in Mango Moi, LLC and substantially all of the property and assets of Mango Moi including without limitation inventory, formulas, packaging, intellectual property, customer lists, websites, domain names, and social media accounts.

 

On March 15, 2022, we entered into a Finder’s Fee Agreement with JH Darbie & Co., Inc. Pursuant to which JH Darbie & Co., Inc. would introduce the Issuer to third-party investors.

 

On April 12, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of April 12, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement we entered into on March 15, 2022 with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

Also on April 12, 2022, we entered into an Agreement to Terminate Amended and Corrected Equity Purchase Agreement (the “Agreement to Terminate”) with WVH to terminate the aforementioned Equity Purchase Agreement, whereby WVH agreed to forfeit the 7,048,873 shares of our common stock that were previously issued to WVH as commitment shares pursuant to the Equity Purchase Agreement.

 

On April 15, 2022, we entered into a Placement Agent Agreement with JH Darbie & Co., Inc. pursuant to which JH Darbie would possibly participate as a sales agent in the private placement of a $5,000,000 Equity Line of Credit.

 

On April 18, 2022, we entered into a Standby Equity Commitment Agreement with MacRab LLC, a Florida limited liability company providing us with an option to sell up to $5,000,000 worth of our common stock, par value $0.0001, to MacRab LLC, in increments, over the period ending 24 months after the date that the Company’s registration statement is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. Additionally, we issued MacRab LLC a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock as a commitment fee in connection with the execution of the Standby Equity Commitment Agreement. We also entered into a Registration Rights Agreement with the Investor requiring the Company to file a registration statement providing for the registration of the common stock issuable to MacRab LLC under the Standby Equity Commitment Agreement and their common stock purchase warrant, and the subsequent resale by MacRab LLC of such common stock. Pursuant to the Placement Agent Agreement entered into on April 15, 2022 with JH Darbie & Co., Inc., the Company will pay to Darbie a fee equal to 3% of the gross proceeds raised from the sale of the securities, including all amounts placed in an escrow account or payable in the future and all amounts paid or payable upon exercise, conversion or exchange of such securities received or receivable directly by the Company. Such consideration paid in cash shall be paid directly to Darbie out of escrow, as and when such consideration is paid to the Company.

 

27

 

 

On April 29, 2022, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, for the consideration and on the terms set forth in the MIPA. Additionally, in accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On May 26, 2022, we closed on the Membership Interest Purchase Agreement (the “MIPA”) and acquired Mango Moi, LLC with a purchase price of $597,726.57 worth of shares of the Company’s common stock, which consisted of 11,000,000 shares of common stock, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be. In accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On June 7, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of June 7, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement we entered into on March 15, 2022 with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021. The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Board of Directors approved and adopted a Code of Business Conduct and Ethics and Compliance Program designed to deter wrongdoing and to promote the types of conduct by directors, executives, and employees to uphold a strong sense of ethics and integrity.

 

On July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022. Also on July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

 

28

 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures 

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our fractional Chief Financial Officer to allow for timely decisions regarding required disclosure. 

 

As of February 5, 2023, our management, with the participation of, and under the supervision of, our Chief Executive Officer and fractional Chief Financial Officer, evaluated the effectiveness of the design and the operation of our disclosure controls and procedures. Based upon that evaluation, management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of May 31, 2022, due to the identification of a material weakness in the Company’s internal control over financial reporting as of May 31, 2022.

 

As disclosed in the Company’s Current Report on Form 8-K filed on March 3, 2023 with the SEC, on February 5, 2023, the Company’s management concluded that the following financial statements should be restated and should no longer be relied upon:

 

(i)The Company’s unaudited consolidated financial statements for the three months ended May 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2022 (the “Q1 2022 10-Q”); and

 

(ii)The Company’s unaudited consolidated financial statements for the three and six months ended August 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on October 21, 2022 (the “Q2 2022 10-Q” and together with the Q1 2022 10-Q, the “Filings”).

 

The following errors impacted the Filings:

 

(i)Incorrect itemization of accounts payable to reflect certain itemized expenses;

 

(ii)Failure to include the rounding up of shares to reflect the correct total number of issued common stock;

 

(iii)Failure to include certain accrued expenses to the accounts payable section;

 

29

 

 

(iv)Incorrect calculation of closing dates regarding the reporting period for goods sold;

 

(v)Incorrect calculation of closing dates regarding the reporting period for costs of goods sold;

 

(vi)Incorrect statement of impaired expenses of $577,473 related to the acquisition of Mango Moi;

 

(vii)Incorrect calculation of stock option agreements with Mast Hill and members of the Company’s Board of Directors;

 

(viii)Incorrect calculation of selling, general and administrative operating expenses, which have been retranslated to comply with reporting standards under GAAP;

 

(ix)Incorrect itemization of stock warrant expenses, reflected in the reitemization of $36,366;

 

(x)Portions of the cash flow section of the financials did not meet GAAP standards;

 

(xi)Omission of unaccounted depreciation in the financial statements; and

 

(xii)Certain other incorrect calculations.

 

The Company has determined that the reporting effects of the above errors had a material impact to the Company’s unaudited consolidated financial statements of the Company for the three months ended May 31, 2022, as reported in the Q1 2022 10-Q, and for the three and six months ended August 31, 2022, as reported in the Q2 2022 10-Q. As a result, the unaudited consolidated financial statements for the three months ended May 31, 2022 and the unaudited consolidated financial statements for the three and six months ended August 31, 2022 will be restated, and the Company will file an amendment to each of the Q1 2022 10-Q and the Q2 2022 10-Q with the SEC.

 

Remediation of Material Weakness

 

We are in the process of implementing improvements and remedial measures in response to the material weakness, including the hiring of a fractional Chief Financial Officer with over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits. Additionally, we entered into an agreement with Aprari Solutions for accounting and audit-related services. Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in GAAP and PCAOB audit standards and procedures. 

 

Changes in Internal Control over Financial Reporting  

 

Since February 5, 2023, and in connection with the evaluation required by Rule 13a-15 under the Exchange Act as of May 31, 2022, the Company has made changes to its internal control over financial reporting that materially affected or are reasonably likely to affect our internal control over financial reporting, including those changes set forth under “—Remediation of Material Weakness.” 

  

Limitations on the effectiveness of internal controls 

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its desired objectives. In addition, the design of disclosure controls and procedures must reflect resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management does not expect the Company’s disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding internal controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. 

 

30

 

 

PART II-OTHER INFORMATION

 

ITEM 1 LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A RISK FACTORS

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 OTHER INFORMATION

 

None.

 

ITEM 6 EXHIBITS

 

Exhibit No.   Description
     
31.1   Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended May 31, 2022.(1)
     
31.2   Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended May 31, 2022.(1)
     
32.1   Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(1)
     
32.2   Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(1)
     
101.INS   Inline XBRL Instance Document.(2)
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.(2)
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.(2)
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.(2)
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.(2)
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.(2)
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(1) Filed herewith.
(2) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

 

31

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Better For You Wellness, Inc.  
(Registrant)  
   
By: /s/ Ian James  
Name: Ian James  
  Chairman and Chief Executive Officer  
  (Principal Executive Officer)  
     
Dated:  March 17, 2023  

 

 

 

32

 

0.00 0.00 195652174 363657794 true --02-28 Q1 0001852707 0001852707 2022-03-01 2022-05-31 0001852707 2023-03-17 0001852707 2022-05-31 0001852707 2022-02-28 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-03-01 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-05-31 0001852707 bfyw:PredecessorsMember 2022-05-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-05-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-29 2021-09-02 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 2021-09-07 2021-09-17 0001852707 bfyw:SRAXIncMember 2021-09-03 2021-09-17 0001852707 bfyw:MastHillFundLPMember 2022-04-12 2022-04-12 0001852707 bfyw:MastHillFundLPMember 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 2022-04-01 2022-04-12 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-05-31 0001852707 2021-09-04 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-02 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2022-04-01 2022-04-13 0001852707 2021-09-03 2021-09-30 0001852707 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2022-02-28 0001852707 bfyw:PaulMoodyMember 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2020-03-01 2021-02-28 0001852707 bfyw:IanJamesMember 2022-03-01 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-01 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-07-11 0001852707 bfyw:DrNicolaFinleyMember 2022-05-31 0001852707 us-gaap:SubsequentEventMember 2022-07-11 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0522a1ex31-1_better.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION

 

I, Ian James, Chairman of the Board and Chief Executive Officer, certify that:

 

1.I have reviewed this amended Quarterly Report on Form 10-Q/A for the quarter ended May 31, 2022 of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

IEvaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 17, 2023

 

/s/ Ian James  
Ian James  

Chairman of the Board and

Chief Executive Officer  

 
(Principal Executive Officer)  

 

 

 

EX-31.2 3 f10q0522a1ex31-2_better.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATIONS

 

I, Pratibha Chaurasia, Fractional Chief Financial Officer, certify that:

 

1.I have reviewed this amended Quarterly Report on Form 10-Q/A for the quarter ended May 31, 2022 of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 17, 2023

 

/s/ Pratibha Chaurasia  
Fractional Chief Financial Officer    
(Principal Financial and Accounting Officer)  

 

 

 

EX-32.1 4 f10q0522a1ex32-1_better.htm CERTIFICATION

 Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the amended Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q/A for the quarter ended May 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Chief Executive Officer of the Company, certify that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 17, 2023 

 

/s/ Ian James  
Ian James  

Chairman of the Board and

Chief Executive Officer  

 
(Principal Executive Officer)  

 

 

EX-32.2 5 f10q0522a1ex32-2_better.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the amended Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q/A for the quarter ended May 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Pratibha Chaurasia, Fractional Chief Financial Officer of the Company, certify that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 17, 2023 

 

/s/ Pratibha Chaurasia  
Fractional Chief Financial Officer    
(Principal Financial and Accounting Officer)  
   

 

 

EX-101.SCH 6 bfyw-20220531.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheet (unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Business Combinations link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Convertible Note Payable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stock Purchase Warrant Liability link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Shareholder Equity link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Related-Party Transactions link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Goodwill link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Business Combinations (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Business Combinations (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Convertible Note Payable (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stock Purchase Warrant Liability (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Shareholder Equity (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 bfyw-20220531_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bfyw-20220531_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bfyw-20220531_lab.xml XBRL LABEL FILE EX-101.PRE 10 bfyw-20220531_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - shares
3 Months Ended
May 31, 2022
Mar. 17, 2023
Document Information Line Items    
Entity Registrant Name BETTER FOR YOU WELLNESS, INC.  
Document Type 10-Q/A  
Current Fiscal Year End Date --02-28  
Entity Common Stock, Shares Outstanding   404,014,987
Amendment Flag true  
Amendment Description Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2022 (the “Original Form 10-Q”).Background of RestatementThis Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed August 9, 2022, the negative net loss was reported as $1,373,066 for the three months ended May 31, 2022. The Amended and Restated negative net loss is reported as $ 891,872 a difference of $481,194 less in net loss for the three month period  ended May 31, 2022.In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Internal Control ConsiderationsIn connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Items Amended in this Amendment No. 1This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended: ●Part I, Item 1, Financial Statements     ●Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations     ●Part I, Item 4, Controls and Procedures     ●Part II, Item 1A, Risk Factors Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement.  
Entity Central Index Key 0001852707  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date May 31, 2022  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-56262  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 87-2903933  
Entity Address, Address Line One 1349 East Broad Street  
Entity Address, City or Town Columbus  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43205  
City Area Code (614)  
Local Phone Number 368-9898  
Entity Interactive Data Current Yes  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheet (unaudited) - USD ($)
May 31, 2022
Feb. 28, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 3,309 $ 9,642
Inventory 7,037
Prepaids and other assets 78,072
Total Current assets 88,418 9,642
Equipment, net 2,129
Goodwill 583,586
TOTAL ASSETS 674,133 9,642
Current Liabilities    
Accounts Payable 161,815 375,408
Deferred Compensation 100,160
Clearbanc Debit Card 2,288
Related Party Notes Payable 35,000
Total Current Liabilities 299,263 375,408
Notes Payable - PayPal Capital 2,335
Notes Payable Shopify Capital 483
Convertible notes payable, net accumulated interest 254,369
TOTAL LIABILITIES 556,449 375,408
Stockholders’ Equity (Deficit)    
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022) 70 70
Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042 issued and outstanding as of May 31, 2022 and February 28, 2022, respectively) 38,012 37,075
Additional paid-in capital 2,609,749 1,485,364
Shares cancellable (250,000)
Accumulated deficit (2,530,147) (1,638,275)
Total Stockholders’ Equity (Deficit) 117,684 (365,766)
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT) $ 674,133 $ 9,642
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) - $ / shares
May 31, 2022
Feb. 28, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 700,000 700,000
Preferred stock, shares outstanding 700,000 700,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 380,108,169 370,747,042
Common stock, shares outstanding 380,108,169 370,747,042
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
Revenue    
Merchandise Sales $ 306  
Cost of Goods Sold 6,069  
Gross Profit (5,763)  
Operating Expenses:    
Share-based expense 684,050  
Selling, General and Administrative 196,995 $ 72,051
Total operating expenses 881,045 72,051
Operating Income/(Loss) (886,808) (72,051)
Other Income/(Expense)    
Other income  
Interest expense (5,063)
Other expense  
Total other expense (5,063)  
Net income/(loss) $ (891,872) $ (72,051)
Basic net loss per common share (in Dollars per share) $ 0 $ 0
Weighted average number of common shares outstanding - Basic (in Shares) 363,657,794 140,868,130
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
May 31, 2022
May 31, 2021
Income Statement [Abstract]    
Diluted net loss per common share $ 0.00 $ 0.00
Weighted average number of common shares outstanding - Diluted 363,657,794 195,652,174
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) - USD ($)
Common
Common
Series A
Series A
Common
Series A
Additional Paid-in-Capital
Shares Cancellable
Noncontrolling Interest
Accumulated Deficit
Total
Balances at Feb. 28, 2021     $ 1,185 $ (4,935)   $ (3,750)    
Balances (in Shares) at Feb. 28, 2021              
Common shares issued after reorganization       $ (36,000)         $ 359,996,332
Common shares issued after reorganization (in Shares)     36,000            
Series A preferred shares issued after reorganization     $ 700,000 $ 69,930   70,000  
Series A preferred shares issued after reorganization (in Shares)     700          
Expenses paid on behalf of the Company and contributed to capital       $ 3,951     3,951    
Net loss         (72,051)   (72,051)   (72,051)
Balances at May. 31, 2021     $ 700,000 $ 39,067 (76,986)   (1,850)   359,996,332
Balances (in Shares) at May. 31, 2021     36,000 700          
Balances at Feb. 28, 2022 $ 37,075 $ 70     1,485,364 $ (250,000) (1,638,275) $ (365,766) (365,766)
Balances (in Shares) at Feb. 28, 2022 370,747,042 700,000              
Common shares cancelled and returned to the Company $ (705)     (249,295) 250,000
Common shares cancelled and returned to the Company (in Shares) (7,048,873)              
Common shares issued for shares payable $ 33     (33)
Common shares issued for shares payable (in Shares) 325,000              
Common shares issued for services to Company $ 509     272,226 272,735  
Common shares issued for services to Company (in Shares) 5,085,000              
Common shares issued for purchase of subsidiary $ 1,100     548,900 550,000  
Common shares issued for purchase of subsidiary (in Shares) 11,000,000              
Stock option expense     411,315 411,315  
Warrants Issued     78,072 78,072  
Warrants Issued         13,514     13,514  
Debt Forgiveness         49,686   49,686  
Net loss         (891,872) (891,872) (891,872)
Balances at May. 31, 2022 $ 38,012 $ 70     $ 2,609,749 $ (2,530,147) $ 117,684 $ 117,684
Balances (in Shares) at May. 31, 2022 380,108,169 700,000              
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Cash Flows - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (891,872) $ (72,051)
Adjustment to reconcile net loss to net cash used in operating activities:    
Share based expenses 684,050 70,000
Amortized debt discount and debt issuance costs 12,139
Depreciation 194
Changes in current assets and liabilities:    
Inventory 6,060
Accounts Payable (213,593) (1,900)
Accrued Interest 5,063
Deferred Compensation 100,160
Other liabilities (6,403)  
Net cash used in Operating Activities (304,202) (3,951)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Fixed Asset (2,323)
Net cash used in Investing Activities (2,323)
CASH FLOWS FROM FINANCING ACTIVITIES    
Payment of debt issuance Cost (28,320)
Proceeds from Convertible loan, net of original issue discount 279,000
Proceed from related party note payable  
Notes Payable – LT (174)  
Noncontrolling interest  
Expenses contributed to capital 49,686 3,951
Net cash provided by financing activities 300,192 3,951
Net change in cash (6,333)  
Beginning cash balance 9,642  
Ending cash balance 3,309  
NON-CASH FINANCING TRANSACTIONS:    
Discount on notes payable for warrants 13,514
Warrants issued and extended for common stock issuance costs $ 78,072
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Organization and Description of Business

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).

 

Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three months ended May 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022 and February 28, 2021, the Company had no deferred revenues.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 was $3,309 and $9,642, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and 2021. Thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation - Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Going Concern
3 Months Ended
May 31, 2022
Going Concern [Abstract]  
Going Concern

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations
3 Months Ended
May 31, 2022
Business Combinations [Abstract]  
Business Combinations

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   537 
Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   May 31,
2022
   May 31,
2021
 
Total revenues  $6,974   $19,455 
Net (loss) income  $(891,872)  $(90,902)
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

   For the
three months  ended
May 31,
   For the
three months   ended
May 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $   6,974   $19,455 
Net income  $(8,281)  $(9,425)
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
3 Months Ended
May 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 5 - Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
3 Months Ended
May 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Note Payable
3 Months Ended
May 31, 2022
Convertible Note Payable Disclosure [Abstract]  
Convertible Note Payable

Note 7 - Convertible Note Payable

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Purchase Warrant Liability
3 Months Ended
May 31, 2022
Stock Purchase Warrant Liability [Abstract]  
Stock Purchase Warrant Liability

Note 8 - Stock Purchase Warrant Liability

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA. The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity
3 Months Ended
May 31, 2022
Shareholder Equity [Abstract]  
Shareholder Equity

Note 9 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May 31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May 31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $15,000.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totalling $68,000.

 

On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $15,468.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $550,000.

 

During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totalling approximately $40,248.

 

Shares Cancellable

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.

 

On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been cancelled and returned to the Company.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 6,500,000 fully vested on May 31, 2022. The remaining 13,500,000 shares vest over the next 2 years. During the three months ended May 31, 2023, no shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.

 

The Company fair valued the options on the grant at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $411,315. The total unamortized stock option expense at May 31, 2022 was approximately $2,151,622.

 

Additional Paid-In Capital

 

During the quarterly period ended May 31, 2022, a total of $2,609,749 posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including negative $249,295 for the termination of the Williamsburg Venture Holdings’ Equity Purchase Agreement, a negative $33 due to a clerical error, the common shares related to these Subscription Agreements were not issued until Q1 of 2022, $411,315 of share option vestment/expense for the Board of Directors, $272,226 for Mast Hill, $548,900 for purchase of Mango Moi Subsidiary/No subsidiary acquired this quarterly filing, and $78,072 in Warrants issued related to MacRab, 13,514 in Warrants related to JH Darbie finder’s agreement and debt treatment of Mast Hill, and $49,686 in debt forgiveness of accrued expense payable to Green Ohio Ventures.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $6,441 during the year ended February 28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totalling $500.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $1,185 during the year ended February 28, 2021.

 

The $8,126 in total payments made by the former directors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions
3 Months Ended
May 31, 2022
Related-Party Transactions [Abstract]  
Related-Party Transactions

Note 10 - Related-Party Transactions

 

Loan to Company

 

During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totalling approximately $2,323 and the Company made payments to Green Ohio Ventures, LLC, totalling approximately $96,079, which resulted in Green Ohio Ventures being owed approximately $0 for loans made to the Company.

 

These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill
3 Months Ended
May 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill

Note 11 – Goodwill

 

In the previous filing, the Company reported an Impairment Expense of $577,473. In recategorization  of the Company’s financials to meet GAAP standards, the Company removed the Impairment Expense related to the Company’s purchase of Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The revised financials now reflect Goodwill in the amount of $583,586.

 

While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three months ended May 31, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred. 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
3 Months Ended
May 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 12 - Subsequent Events

 

On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.

 

The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Accounting Policies, by Policy (Policies)
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Revenue Recognition

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022 and February 28, 2021, the Company had no deferred revenues.

 

Basis of Presentation

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 was $3,309 and $9,642, respectively.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

Basic Earnings (Loss) Per Share

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and 2021.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

Share-Based Compensation

 

ASC 718, “Compensation - Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Tables)
3 Months Ended
May 31, 2022
Business Combinations [Abstract]  
Schedule of fair value of such assets and liabilities
Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   537 
Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

Schedule of condensed consolidated results of operations
   For the Three months ended 
   (unaudited)   (unaudited) 
   May 31,
2022
   May 31,
2021
 
Total revenues  $6,974   $19,455 
Net (loss) income  $(891,872)  $(90,902)
Loss per share  $
-
   $
-
 

 

Schedule of amounts of revenue and earnings of mango moi
   For the
three months  ended
May 31,
   For the
three months   ended
May 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $   6,974   $19,455 
Net income  $(8,281)  $(9,425)
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business (Details) - USD ($)
1 Months Ended
Sep. 02, 2021
Aug. 25, 2021
Aug. 24, 2021
Jul. 30, 2021
Jul. 18, 2021
May 31, 2022
Apr. 29, 2022
Feb. 28, 2022
Organization and Description of Business (Details) [Line Items]                
Independent director agreements, description we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share.              
Common stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001
Shares of common stock           500,000,000   500,000,000
Fair market value (in Dollars)             $ 550,000  
Common stock, shares issued           380,108,169   370,747,042
Fast Track Solutions, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock         250,000,000      
Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage   5.00%            
Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage       89.62%        
Paid consideration (in Dollars)       $ 335,000        
Predecessor [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
CRS Consulting, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock       250,000,000        
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shareholder owning preferred stock         700,000      
Sale of shares       700,000        
CRS Consulting, LLC [Member] | Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage       89.62%        
Ian James [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares       350,000        
Stephen Letourneau [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares       350,000        
Green Ohio Ventures, LLC [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock       250,000,000        
MRKTS Group Inc [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock     17,963,817          
MRKTS Group Inc [Member] | Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage     5.00%          
Better for You Wellness, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock   24,137,499            
Mango Moi, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, par value (in Dollars per share)             $ 0.0001  
Shares of common stock             11,000,000  
Amanda Cayemitte [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,720,000  
Yapo M’be [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,280,000  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended
May 31, 2022
Feb. 28, 2022
Organization and Description of Business [Abstract]    
Significant Accounting Policies and Use of Estimates

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three months ended May 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

 
Cash and cash equivalents $ 3,309 $ 9,642
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

 
Reclassification of Prior Year Presentation

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details)
3 Months Ended
May 31, 2022
USD ($)
Business Combinations [Abstract]  
Purchase price of stock $ 592,000
Goodwill $ 583,586
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of fair value of such assets and liabilities
May 31, 2022
USD ($)
Schedule Of Fair Value Of Such Assets And Liabilities Abstract  
Cash $ 913
Inventory 12,995
Total Assets Acquired 13,908
Clearbanc Debit Card 2,365
Notes Payable - PayPal Capital 2,454
Notes Payable Shopify Capital 537
Sales Tax Payable 138
Total Liabilities Assumed 5,494
Total identifiable net assets 8,414
Purchase price 592,000
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date $ 583,586
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of condensed consolidated results of operations - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
Schedule Of Condensed Consolidated Results Of Operations Abstract    
Total revenues $ 6,974 $ 19,455
Net (loss) income $ (891,872) $ (90,902)
Loss per share (in Dollars per share)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
Schedule Of Amounts Of Revenue And Earnings Of Mango Moi Abstract    
Total revenues $ 6,974 $ 19,455
Net income $ (8,281) $ (9,425)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended
Sep. 17, 2021
Sep. 17, 2021
May 31, 2022
Commitments and Contingencies (Details) [Line Items]      
Common stock purchase warrant for purchase $ 30,500,000    
Associated expenses 15,000    
Immediately purchase $ 250,000    
Restricted common stock discount percentage 15.00%    
Outstanding shares percentage 4.99%    
Amount paid     $ 22,320
Annual salary of payable     $ 65,000
Consulting agreement, description     Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.
SRAX [Member]      
Commitments and Contingencies (Details) [Line Items]      
Amount paid   $ 20,000  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Note Payable (Details)
Apr. 12, 2022
USD ($)
Apr. 12, 2022
USD ($)
$ / shares
shares
Convertible Note Payable (Details) [Line Items]    
Principal amount $ 310,000  
Purchase price 279,000 $ 279,000
Discount amount $ 31,000 $ 31,000
Interest rate   12.00%
Maturity date Apr. 12, 2023 Apr. 12, 2023
Common stock conversion price per share (in Dollars per share) | $ / shares   $ 0.037
Mast Hill Fund, L.P., [Member]    
Convertible Note Payable (Details) [Line Items]    
Principal amount   $ 310,000
Purchase price $ 279,000 $ 279,000
Commitment shares (in Shares) | shares   4,960,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Purchase Warrant Liability (Details)
1 Months Ended
Apr. 18, 2022
Stock Purchase Warrant Liability [Abstract]  
Stock purchase warrant liability description Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA. The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 13, 2022
Apr. 12, 2022
Jan. 13, 2022
Jan. 03, 2022
Oct. 11, 2021
Sep. 17, 2021
Aug. 25, 2021
May 26, 2022
Nov. 17, 2021
Sep. 30, 2021
Aug. 24, 2021
Jul. 19, 2021
May 31, 2022
May 31, 2021
Feb. 28, 2022
Feb. 28, 2021
Dec. 02, 2021
Nov. 30, 2021
Shareholder Equity (Details) [Line Items]                                    
Preferred stock, shares authorized                         200,000,000   200,000,000      
Preferred stock, par value (in Dollars per share)                         $ 0.0001   $ 0.0001      
Preferred stock, shares issued                         700,000   700,000      
Preferred stock, shares outstanding                         700,000   700,000      
Preferred stock, voting rights                         Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock.          
Common stock, shares authorized                         500,000,000   500,000,000      
Common stock, par value (in Dollars per share)                         $ 0.0001   $ 0.0001      
Common stock, shares issued                         380,108,169   370,747,042      
Common stock, shares outstanding                         380,108,169   370,747,042      
Principal amount (in Dollars)   $ 310,000                                
Purchase price (in Dollars)   279,000                                
Discount amount (in Dollars)   $ 31,000                                
Bears interest rate   12.00%                                
Conversion price (in Dollars per share)   $ 0.037                                
Commitment shares                         4,960,000          
Common stock value (in Dollars)           $ 30,500,000                        
Cover expenses (in Dollars)           $ 15,000                        
Common stock closing price, percentage           15.00%                        
Grant option exercisable                             20,000,000      
Number of vested shares                   6,500,000                
Stock option, description                         13,500,000 shares vest over the next 2 years.          
Exercise price per shares (in Dollars per share)                         $ 25          
Stock option expire term                             5 years      
Stock option outstanding intrinsic value (in Dollars)                         $ 0          
Stock price description                         stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants).          
Stock options fair value the grant date (in Dollars per share)                         $ 2,127,565          
The total stock option expense (in Dollars)                         $ 411,315          
Total unamortized stock option expense (in Dollars)                         2,151,622          
Additional paid-in capita (in Dollars)                         $ 2,609,749   $ 1,485,364      
Equity purchase agreement, description                         This includes Common Shares issued for services for the Company including negative $249,295 for the termination of the Williamsburg Venture Holdings’ Equity Purchase Agreement, a negative $33 due to a clerical error, the common shares related to these Subscription Agreements were not issued until Q1 of 2022, $411,315 of share option vestment/expense for the Board of Directors, $272,226 for Mast Hill, $548,900 for purchase of Mango Moi Subsidiary/No subsidiary acquired this quarterly filing, and $78,072 in Warrants issued related to MacRab, 13,514 in Warrants related to JH Darbie finder’s agreement and debt treatment of Mast Hill, and $49,686 in debt forgiveness of accrued expense payable to Green Ohio Ventures.           
Paid expenses (in Dollars)                                  
Total payments considered contributions (in Dollars)                         $ 8,126          
Series A Preferred Stock [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Preferred stock, shares issued                                   350,000
Series A preferred stock were issued                         700,000          
Shares of restricted common stock                         250,000,000          
Board of Directors [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock   125,000   125,000         125,000                  
Closing share price (in Dollars)   $ 15,468   $ 15,000         $ 18,750                  
Jeffrey DeNunzio [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Paid expenses (in Dollars)                             6,441 $ 1,185    
CRS Consulting, LLC [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock         250,000           50,000              
Closing share price (in Dollars)         $ 45,000           $ 7,000              
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Series A preferred stock were issued                           700,000        
Sauer Energy, Inc. [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Common shares, outstanding                         359,996,332          
Green Ohio Ventures, LLC [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock             24,137,499       17,963,817 250,000,000            
SRAX, Inc [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock         2,602,740                          
Closing share price (in Dollars)         $ 468,493                          
Shareholders [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock     549,097                   325,000          
Proceeds total (in Dollars)     $ 68,000                   $ 40,248          
Mango Moi, LLC [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Restricted common stock               11,000,000                    
Closing share price (in Dollars)               $ 550,000                    
Williamsburg Venture Holdings LLC [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Common stock, shares issued                                 7,048,873  
Purchase price of shares (in Dollars)                                 $ 250,000  
Cancellation and return of common shares 7,048,873                                  
Paul Moody [Member]                                    
Shareholder Equity (Details) [Line Items]                                    
Paid expenses (in Dollars)                             $ 500      
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions (Details)
3 Months Ended
May 31, 2022
USD ($)
Related-Party Transactions (Details) [Line Items]  
Loan Amount $ 0
Ian James [Member]  
Related-Party Transactions (Details) [Line Items]  
Paid expenses 2,323
Green Ohio Ventures, LLC [Member]  
Related-Party Transactions (Details) [Line Items]  
Paid expenses 96,079
Mango Moi, LLC [Member]  
Related-Party Transactions (Details) [Line Items]  
Paid expenses $ 35,000
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill (Details)
3 Months Ended
May 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill impairment expense $ 577,473
Goodwill $ 583,586
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details) - USD ($)
3 Months Ended
Jun. 07, 2022
May 31, 2022
Jul. 11, 2022
Apr. 12, 2022
Subsequent Events (Details) [Line Items]        
Original issue discount       $ 31,000
Maturity date   Jun. 07, 2023    
Commitment shares (in Shares)   4,960,000    
Purchase agreement description   In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.     
Agreement fees   $ 22,320    
Warrant coverage raised percentage   8.00%    
Exercise price percentage   120.00%    
Registration rights expires   5 years    
Subsequent Event [Member]        
Subsequent Events (Details) [Line Items]        
Principal amount     $ 1  
Purchase price $ 279,000      
Original issue discount $ 31,000      
Interest rate 12.00%      
Conversion price per share (in Dollars per share) $ 0.037      
Dr. Nicola Finley [Member]        
Subsequent Events (Details) [Line Items]        
Purchase common shares (in Shares)   4,000,000    
Securities Purchase Agreement [Member] | Subsequent Event [Member]        
Subsequent Events (Details) [Line Items]        
Principal amount $ 310,000      
Subsequent Event [Member]        
Subsequent Events (Details) [Line Items]        
Common stock value (in Shares)     4,000,000  
XML 45 f10q0522a1_better_htm.xml IDEA: XBRL DOCUMENT 0001852707 2022-03-01 2022-05-31 0001852707 2023-03-17 0001852707 2022-05-31 0001852707 2022-02-28 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-03-01 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-05-31 0001852707 bfyw:PredecessorsMember 2022-05-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-05-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-29 2021-09-02 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 2021-09-07 2021-09-17 0001852707 bfyw:SRAXIncMember 2021-09-03 2021-09-17 0001852707 bfyw:MastHillFundLPMember 2022-04-12 2022-04-12 0001852707 bfyw:MastHillFundLPMember 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 2022-04-01 2022-04-12 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-05-31 0001852707 2021-09-04 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-02 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2022-04-01 2022-04-13 0001852707 2021-09-03 2021-09-30 0001852707 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2022-02-28 0001852707 bfyw:PaulMoodyMember 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2020-03-01 2021-02-28 0001852707 bfyw:IanJamesMember 2022-03-01 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-01 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-07-11 0001852707 bfyw:DrNicolaFinleyMember 2022-05-31 0001852707 us-gaap:SubsequentEventMember 2022-07-11 shares iso4217:USD iso4217:USD shares pure 10-Q/A true 2022-05-31 false 000-56262 BETTER FOR YOU WELLNESS, INC. NV 87-2903933 1349 East Broad Street Columbus OH 43205 (614) 368-9898 Yes Yes Non-accelerated Filer false true false false 2023 404014987 Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2022 (the “Original Form 10-Q”).Background of RestatementThis Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed August 9, 2022, the negative net loss was reported as $1,373,066 for the three months ended May 31, 2022. The Amended and Restated negative net loss is reported as $ 891,872 a difference of $481,194 less in net loss for the three month period  ended May 31, 2022.In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Internal Control ConsiderationsIn connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Items Amended in this Amendment No. 1This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended: ●Part I, Item 1, Financial Statements     ●Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations     ●Part I, Item 4, Controls and Procedures     ●Part II, Item 1A, Risk Factors Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement. 3309 9642 7037 78072 88418 9642 2129 583586 674133 9642 161815 375408 100160 2288 35000 299263 375408 2335 483 254369 556449 375408 0.0001 0.0001 200000000 200000000 700000 700000 700000 700000 70 70 0.0001 0.0001 500000000 500000000 380108169 380108169 370747042 370747042 38012 37075 2609749 1485364 -250000 -2530147 -1638275 117684 -365766 674133 9642 306 6069 -5763 684050 196995 72051 881045 72051 -886808 -72051 5063 -5063 -891872 -72051 0 0 363657794 140868130 370747042 37075 700000 70 1485364 -250000 -1638275 -365766 -7048873 -705 -249295 250000 325000 33 -33 5085000 509 272226 272735 11000000 1100 548900 550000 411315 411315 78072 78072 13514 13514 49686 49686 -891872 -891872 380108169 38012 700000 70 2609749 -2530147 117684 1185 -4935 -3750 359996332 36000 -36000 700000 700 69930 70000 3951 3951 -72051 -72051 359996332 36000 700000 700 39067 -76986 -1850 -891872 -72051 684050 70000 12139 194 -6060 -213593 -1900 5063 100160 -6403 -304202 -3951 2323 -2323 28320 279000 -174 49686 3951 300192 3951 -6333 9642 3309 13514 78072 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Organization and Description of Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected February 28th as its year end.</p> 1000 1000 700000 250000000 700000 250000000 0.8962 350000 350000 250000000 335000 0.8962 17963817 0.05 24137499 0.05 we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. 0.0001 11000000 550000 5720000 5280000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Significant Accounting Policies and Use of Estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There were no material changes in the Company’s significant accounting policies for the three months ended May 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b> </b></span></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022 and February 28, 2021, the Company had no deferred revenues.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 was $3,309 and $9,642, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company does not have any potentially dilutive instruments as of May 31, 2022 and 2021. Thus, anti-dilution issues are not applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation - Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.” </i>Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Reclassification of Prior Year Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Significant Accounting Policies and Use of Estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There were no material changes in the Company’s significant accounting policies for the three months ended May 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b> </b></span></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022 and February 28, 2021, the Company had no deferred revenues.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 was $3,309 and $9,642, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 3309 9642 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>The Company does not have any potentially dilutive instruments as of May 31, 2022 and 2021. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation - Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.” </i>Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Reclassification of Prior Year Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 3 - Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Note 4 - Business Combinations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true">Assets acquired:</b></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">913</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Inventory</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">12,995</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Assets Acquired</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">13,908</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><b style="-keep: true">Liabilities assumed:</b></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Clearbanc Debit Card</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">2,365</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Notes Payable - PayPal Capital</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">2,454</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Notes Payable Shopify Capital</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="font-size: 10pt">537</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Sales Tax Payable</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">138</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Liabilities Assumed</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">5,494</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Total identifiable net assets</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">8,414</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Purchase price</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">592,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">583,586</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b style="-keep: true">For the Three months ended</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">(unaudited)</b></td><td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">(unaudited)</b></td><td><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">May 31,<br/> 2022</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">May 31,<br/> 2021</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total revenues</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="-keep: true">6,974</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="-keep: true">19,455</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Net (loss) income</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(891,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(90,902</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Loss per share</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">For the <br/> three months  ended<br/> May 31,</b></td><td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">For the<br/> three months   ended<br/> May 31,</b></td><td><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">2022</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">2021</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Mango Moi:</span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Total revenues</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">   6,974</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">19,455</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Net income</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(8,281</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(9,425</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true">Assets acquired:</b></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">913</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Inventory</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">12,995</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Assets Acquired</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">13,908</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><b style="-keep: true">Liabilities assumed:</b></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Clearbanc Debit Card</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">2,365</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Notes Payable - PayPal Capital</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">2,454</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Notes Payable Shopify Capital</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="font-size: 10pt">537</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Sales Tax Payable</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">138</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Liabilities Assumed</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">5,494</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Total identifiable net assets</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true">8,414</span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Purchase price</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">592,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true"> </span></td><td style="text-align: right"><span style="-keep: true"> </span></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">583,586</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p> 913 12995 13908 2365 2454 537 138 5494 8414 592000 583586 592000 583586 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b style="-keep: true">For the Three months ended</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">(unaudited)</b></td><td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">(unaudited)</b></td><td><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">May 31,<br/> 2022</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">May 31,<br/> 2021</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total revenues</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="-keep: true">6,974</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="-keep: true">19,455</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Net (loss) income</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(891,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(90,902</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Loss per share</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p> 6974 19455 -891872 -90902 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">For the <br/> three months  ended<br/> May 31,</b></td><td><b style="-keep: true"> </b></td><td><b style="-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">For the<br/> three months   ended<br/> May 31,</b></td><td><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">2022</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">2021</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Mango Moi:</span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Total revenues</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">   6,974</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">19,455</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Net income</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(8,281</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(9,425</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr> </table> 6974 19455 -8281 -9425 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 5 - Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 6 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 450-20, <i>Los</i>s <i>Contingencies, </i>to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">one month upon completion of one full calendar year of employment with the Company;</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">two months upon completion of two full calendar years of employment with the Company, and</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">three months upon competition of two full calendar years of employment with the Company.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Consulting Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.</p> 30500000 15000 250000 0.15 0.0499 20000 65000 Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 7 - Convertible Note Payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</p> 310000 279000 31000 0.12 2023-04-12 0.037 4960000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 8 - Stock Purchase Warrant Liability</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA. The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.</span></p> Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA. The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 9 - Shareholder Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May 31, 2022 and February 28, 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $7,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $468,493.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $45,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $18,750.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled $15,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totalling $68,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $15,468.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totalled approximately $550,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totalling approximately $40,248.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Shares Cancellable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been cancelled and returned to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 6,500,000 fully vested on May 31, 2022. The remaining 13,500,000 shares vest over the next 2 years. During the three months ended May 31, 2023, no shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company fair valued the options on the grant at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $411,315. The total unamortized stock option expense at May 31, 2022 was approximately $2,151,622.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional Paid-In Capital</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the quarterly period ended May 31, 2022, a total of $2,609,749 posted as additional paid-in capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">This includes Common Shares issued for services for the Company including negative $249,295 for the termination of the Williamsburg Venture Holdings’ Equity Purchase Agreement, a negative $33 due to a clerical error, the common shares related to these Subscription Agreements were not issued until Q1 of 2022, $411,315 of share option vestment/expense for the Board of Directors, $272,226 for Mast Hill, $548,900 for purchase of Mango Moi Subsidiary/No subsidiary acquired this quarterly filing, and $78,072 in Warrants issued related to MacRab, 13,514 in Warrants related to JH Darbie finder’s agreement and debt treatment of Mast Hill, and $49,686 in debt forgiveness of accrued expense payable to Green Ohio Ventures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $6,441 during the year ended February 28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totalling $500.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totalling $1,185 during the year ended February 28, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $8,126 in total payments made by the former directors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.</p> 200000000 0.0001 700000 700000 700000 700000 700000 700000 250000000 Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. 350000 500000000 0.0001 380108169 380108169 370747042 370747042 359996332 250000000 17963817 24137499 50000 7000 2602740 468493 250000 45000 125000 18750 125000 15000 310000 279000 31000 0.12 0.037 4960000 549097 68000 125000 15468 11000000 550000 325000 40248 30500000 15000 0.15 7048873 250000 7048873 20000000 6500000 13,500,000 shares vest over the next 2 years. 25 P5Y 0 2127565 stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). 411315 2151622 2609749 This includes Common Shares issued for services for the Company including negative $249,295 for the termination of the Williamsburg Venture Holdings’ Equity Purchase Agreement, a negative $33 due to a clerical error, the common shares related to these Subscription Agreements were not issued until Q1 of 2022, $411,315 of share option vestment/expense for the Board of Directors, $272,226 for Mast Hill, $548,900 for purchase of Mango Moi Subsidiary/No subsidiary acquired this quarterly filing, and $78,072 in Warrants issued related to MacRab, 13,514 in Warrants related to JH Darbie finder’s agreement and debt treatment of Mast Hill, and $49,686 in debt forgiveness of accrued expense payable to Green Ohio Ventures.  6441 500 1185 8126 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 10 - Related-Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loan to Company</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totalling approximately $2,323 and the Company made payments to Green Ohio Ventures, LLC, totalling approximately $96,079, which resulted in Green Ohio Ventures being owed approximately $0 for loans made to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary.</span></p> 2323 96079 0 35000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 11 – Goodwill</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In the previous filing, the Company reported an Impairment Expense of $577,473. In recategorization  of the Company’s financials to meet GAAP standards, the Company removed the Impairment Expense related to the Company’s purchase of Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The revised financials now reflect Goodwill in the amount of $583,586.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three months ended May 31, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred. </span></p> 577473 583586 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Note 12 - Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JH Darbie &amp; Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.</p> 310000 279000 31000 0.12 2023-06-07 0.037 4960000 In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.  22320 0.08 1.20 P5Y 4000000 4000000 1 0.00 0.00 195652174 363657794 true --02-28 Q1 0001852707 EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 99 233 1 false 34 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.betterforyouwellness.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheet (unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheet (unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Deficit) Sheet http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statement of Changes in Stockholders??? Equity (Deficit) Statements 6 false false R7.htm 006 - Statement - Consolidated Statement of Cash Flows Sheet http://www.betterforyouwellness.com/role/ConsolidatedCashFlow Consolidated Statement of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Going Concern Sheet http://www.betterforyouwellness.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 010 - Disclosure - Business Combinations Sheet http://www.betterforyouwellness.com/role/BusinessCombinations Business Combinations Notes 11 false false R12.htm 011 - Disclosure - Income Taxes Sheet http://www.betterforyouwellness.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Commitments and Contingencies Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Convertible Note Payable Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayable Convertible Note Payable Notes 14 false false R15.htm 014 - Disclosure - Stock Purchase Warrant Liability Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability Stock Purchase Warrant Liability Notes 15 false false R16.htm 015 - Disclosure - Shareholder Equity Sheet http://www.betterforyouwellness.com/role/ShareholderEquity Shareholder Equity Notes 16 false false R17.htm 016 - Disclosure - Related-Party Transactions Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactions Related-Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Goodwill Sheet http://www.betterforyouwellness.com/role/Goodwill Goodwill Notes 18 false false R19.htm 018 - Disclosure - Subsequent Events Sheet http://www.betterforyouwellness.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 020 - Disclosure - Business Combinations (Tables) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.betterforyouwellness.com/role/BusinessCombinations 21 false false R22.htm 021 - Disclosure - Organization and Description of Business (Details) Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness 22 false false R23.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 23 false false R24.htm 023 - Disclosure - Business Combinations (Details) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 24 false false R25.htm 024 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities Sheet http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable Business Combinations (Details) - Schedule of fair value of such assets and liabilities Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 25 false false R26.htm 025 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations Sheet http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable Business Combinations (Details) - Schedule of condensed consolidated results of operations Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 26 false false R27.htm 026 - Disclosure - Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi Sheet http://www.betterforyouwellness.com/role/ScheduleofamountsofrevenueandearningsofmangomoiTable Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 27 false false R28.htm 027 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.betterforyouwellness.com/role/CommitmentsandContingencies 28 false false R29.htm 028 - Disclosure - Convertible Note Payable (Details) Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails Convertible Note Payable (Details) Details http://www.betterforyouwellness.com/role/ConvertibleNotePayable 29 false false R30.htm 029 - Disclosure - Stock Purchase Warrant Liability (Details) Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails Stock Purchase Warrant Liability (Details) Details http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability 30 false false R31.htm 030 - Disclosure - Shareholder Equity (Details) Sheet http://www.betterforyouwellness.com/role/ShareholderEquityDetails Shareholder Equity (Details) Details http://www.betterforyouwellness.com/role/ShareholderEquity 31 false false R32.htm 031 - Disclosure - Related-Party Transactions (Details) Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.betterforyouwellness.com/role/RelatedPartyTransactions 32 false false R33.htm 032 - Disclosure - Goodwill (Details) Sheet http://www.betterforyouwellness.com/role/GoodwillDetails Goodwill (Details) Details http://www.betterforyouwellness.com/role/Goodwill 33 false false R34.htm 033 - Disclosure - Subsequent Events (Details) Sheet http://www.betterforyouwellness.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.betterforyouwellness.com/role/SubsequentEvents 34 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0522a1_better.htm 3964, 3965, 3966, 3967 f10q0522a1_better.htm bfyw-20220531.xsd bfyw-20220531_cal.xml bfyw-20220531_def.xml bfyw-20220531_lab.xml bfyw-20220531_pre.xml f10q0522a1ex31-1_better.htm f10q0522a1ex31-2_better.htm f10q0522a1ex32-1_better.htm f10q0522a1ex32-2_better.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0522a1_better.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 323, "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 99, "dts": { "calculationLink": { "local": [ "bfyw-20220531_cal.xml" ] }, "definitionLink": { "local": [ "bfyw-20220531_def.xml" ] }, "inline": { "local": [ "f10q0522a1_better.htm" ] }, "labelLink": { "local": [ "bfyw-20220531_lab.xml" ] }, "presentationLink": { "local": [ "bfyw-20220531_pre.xml" ] }, "schema": { "local": [ "bfyw-20220531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 342, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 53, "http://www.betterforyouwellness.com/20220531": 17, "http://xbrl.sec.gov/dei/2022": 4, "total": 74 }, "keyCustom": 41, "keyStandard": 192, "memberCustom": 22, "memberStandard": 11, "nsprefix": "bfyw", "nsuri": "http://www.betterforyouwellness.com/20220531", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Going Concern", "menuCat": "Notes", "order": "10", "role": "http://www.betterforyouwellness.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "11", "role": "http://www.betterforyouwellness.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://www.betterforyouwellness.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "13", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Convertible Note Payable", "menuCat": "Notes", "order": "14", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayable", "shortName": "Convertible Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Stock Purchase Warrant Liability", "menuCat": "Notes", "order": "15", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability", "shortName": "Stock Purchase Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Shareholder Equity", "menuCat": "Notes", "order": "16", "role": "http://www.betterforyouwellness.com/role/ShareholderEquity", "shortName": "Shareholder Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Related-Party Transactions", "menuCat": "Notes", "order": "17", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Goodwill", "menuCat": "Notes", "order": "18", "role": "http://www.betterforyouwellness.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "19", "role": "http://www.betterforyouwellness.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheet (unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheet (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "20", "role": "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Business Combinations (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c52", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "22", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c52", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "23", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SupplementalDeferredPurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Business Combinations (Details)", "menuCat": "Details", "order": "24", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails", "shortName": "Business Combinations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SupplementalDeferredPurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "menuCat": "Details", "order": "25", "role": "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable", "shortName": "Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations", "menuCat": "Details", "order": "26", "role": "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable", "shortName": "Business Combinations (Details) - Schedule of condensed consolidated results of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi", "menuCat": "Details", "order": "27", "role": "http://www.betterforyouwellness.com/role/ScheduleofamountsofrevenueandearningsofmangomoiTable", "shortName": "Business Combinations (Details) - Schedule of amounts of revenue and earnings of mango moi", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c57", "decimals": "0", "first": true, "lang": null, "name": "bfyw:CommonStockPurchaseWarrantForPurchase", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "28", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c57", "decimals": "0", "first": true, "lang": null, "name": "bfyw:CommonStockPurchaseWarrantForPurchase", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c76", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Convertible Note Payable (Details)", "menuCat": "Details", "order": "29", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "shortName": "Convertible Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c62", "decimals": "2", "lang": null, "name": "us-gaap:ShortTermDebtInterestRateIncrease", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheet (unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c63", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Stock Purchase Warrant Liability (Details)", "menuCat": "Details", "order": "30", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails", "shortName": "Stock Purchase Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c63", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Shareholder Equity (Details)", "menuCat": "Details", "order": "31", "role": "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "shortName": "Shareholder Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:PreferredStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Related-Party Transactions (Details)", "menuCat": "Details", "order": "32", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Goodwill (Details)", "menuCat": "Details", "order": "33", "role": "http://www.betterforyouwellness.com/role/GoodwillDetails", "shortName": "Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c61", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "34", "role": "http://www.betterforyouwellness.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "menuCat": "Statements", "order": "6", "role": "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statement of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "8", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522a1_better.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 34, "tag": { "bfyw_AmandaCayemitteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amanda Cayemitte Member", "terseLabel": "Amanda Cayemitte [Member]" } } }, "localname": "AmandaCayemitteMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_BetterForYouWellnessIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Better For You Wellness Inc Member", "terseLabel": "Better for You Wellness, Inc. [Member]" } } }, "localname": "BetterForYouWellnessIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_BusinessAcquisitionsNetIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisitions Net Income Loss", "terseLabel": "Net (loss) income" } } }, "localname": "BusinessAcquisitionsNetIncomeLoss", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "bfyw_CRSConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsulting LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultings LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_CancellationAndReturnOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cancellation and return of common shares.", "label": "Cancellation And Return Of Common Shares", "terseLabel": "Cancellation and return of common shares" } } }, "localname": "CancellationAndReturnOfCommonShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_CashFlowsFromInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities Abstract", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "CashFlowsFromInvestingActivitiesAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "bfyw_ClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "Closing Share Price", "terseLabel": "Closing share price (in Dollars)" } } }, "localname": "ClosingSharePrice", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_CommitmentShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment shares.", "label": "Commitment Share", "terseLabel": "Commitment shares" } } }, "localname": "CommitmentShare", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_CommitmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of commitment shares.", "label": "Commitment Shares", "terseLabel": "Commitment shares (in Shares)" } } }, "localname": "CommitmentShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "bfyw_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommonStockClosingPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of common stock closing price.", "label": "Common Stock Closing Price Percentage", "terseLabel": "Common stock closing price, percentage" } } }, "localname": "CommonStockClosingPricePercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "bfyw_CommonStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock conversion price per share.", "label": "Common Stock Conversion Price Per Share", "terseLabel": "Common stock conversion price per share (in Dollars per share)" } } }, "localname": "CommonStockConversionPricePerShare", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "perShareItemType" }, "bfyw_CommonStockPurchaseWarrantForPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of common stock purchase warrant for purchase.", "label": "Common Stock Purchase Warrant For Purchase", "terseLabel": "Common stock purchase warrant for purchase" } } }, "localname": "CommonStockPurchaseWarrantForPurchase", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_ConsultingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreement description.", "label": "Consulting Agreement Description", "terseLabel": "Consulting agreement, description" } } }, "localname": "ConsultingAgreementDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price per share.", "label": "Conversion Price Per Share", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "ConversionPricePerShare", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "bfyw_ConvertibleNotePayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Line Items]" } } }, "localname": "ConvertibleNotePayableDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Table]" } } }, "localname": "ConvertibleNotePayableDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Disclosure [Abstract]" } } }, "localname": "ConvertibleNotePayableLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable [Table]" } } }, "localname": "ConvertibleNotePayableTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_CoverExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cover expenses.", "label": "Cover Expenses", "terseLabel": "Cover expenses (in Dollars)" } } }, "localname": "CoverExpenses", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_DiscountOnNotesPayableForWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of discount on notes payable for warrants.", "label": "Discount On Notes Payable For Warrants", "terseLabel": "Discount on notes payable for warrants" } } }, "localname": "DiscountOnNotesPayableForWarrants", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_DrNicolaFinleyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr Nicola Finley Member", "terseLabel": "Dr. Nicola Finley [Member]" } } }, "localname": "DrNicolaFinleyMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_EquityPurchaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity purchase agreement, description.", "label": "Equity Purchase Agreement Description", "terseLabel": "Equity purchase agreement, description" } } }, "localname": "EquityPurchaseAgreementDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ExercisePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price.", "label": "Exercise Price Percentage", "terseLabel": "Exercise price percentage" } } }, "localname": "ExercisePricePercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bfyw_ExpensesContributedToCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses contributed to capital.", "label": "Expenses Contributed To Capital", "terseLabel": "Expenses contributed to capital" } } }, "localname": "ExpensesContributedToCapital", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_FairMarketValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair market value.", "label": "Fair Market Value", "terseLabel": "Fair market value (in Dollars)" } } }, "localname": "FairMarketValue", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_FastTrackSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fast Track Solutions Inc Member", "terseLabel": "Fast Track Solutions, Inc. [Member]" } } }, "localname": "FastTrackSolutionsIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GreenOhioVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Green Ohio Ventures LLCMember", "terseLabel": "Green Ohio Ventures, LLC [Member]" } } }, "localname": "GreenOhioVenturesLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ian James Member", "terseLabel": "Ian James [Member]" } } }, "localname": "IanJamesMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ImmediatelyPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of immediately purchase.", "label": "Immediately Purchase", "terseLabel": "Immediately purchase" } } }, "localname": "ImmediatelyPurchase", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_JeffreyDeNunzioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jeffrey De Nunzio Member", "terseLabel": "Jeffrey DeNunzio [Member]" } } }, "localname": "JeffreyDeNunzioMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MRKTSGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MRKTSGroup Inc Member", "terseLabel": "MRKTS Group Inc [Member]" } } }, "localname": "MRKTSGroupIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi LLCMember", "terseLabel": "Mango Moi, LLC [Member]" } } }, "localname": "MangoMoiLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MastHillFundLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mast Hill Fund LPMember", "terseLabel": "Mast Hill Fund, L.P., [Member]" } } }, "localname": "MastHillFundLPMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "domainItemType" }, "bfyw_MerchandiseSalesAmount": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Merchandise sales amount.", "label": "Merchandise Sales Amount", "terseLabel": "Merchandise Sales" } } }, "localname": "MerchandiseSalesAmount", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income Expense Abstract", "terseLabel": "Other Income/(Expense)" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "bfyw_PaulMoodyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paul Moody Member", "terseLabel": "Paul Moody [Member]" } } }, "localname": "PaulMoodyMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_PredecessorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Predecessors Member", "terseLabel": "Predecessor [Member]" } } }, "localname": "PredecessorsMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PurchaseOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase of common stock.", "label": "Purchase Of Common Stock", "terseLabel": "Common stock value (in Dollars)" } } }, "localname": "PurchaseOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Price Member", "terseLabel": "Purchase Price [Member]" } } }, "localname": "PurchasePriceMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PurchasePriceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchase price of shares.", "label": "Purchase Price Of Shares", "terseLabel": "Purchase price of shares (in Dollars)" } } }, "localname": "PurchasePriceOfShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related parties.", "label": "Related Parties Policy Text Block", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "bfyw_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Table]" } } }, "localname": "RelatedPartyTransactionsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "bfyw_RestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares restricted common stock.", "label": "Restricted Common Stock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RestrictedCommonStockDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted common stock discount percentage.", "label": "Restricted Common Stock Discount Percentage", "terseLabel": "Restricted common stock discount percentage" } } }, "localname": "RestrictedCommonStockDiscountPercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_RestrictedCommonStocks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stocks.", "label": "Restricted Common Stocks", "terseLabel": "Restricted common stock" } } }, "localname": "RestrictedCommonStocks", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "Revenue Abstract", "terseLabel": "Revenue" } } }, "localname": "RevenueAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "bfyw_SRAXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SRAXInc Member", "terseLabel": "SRAX [Member]", "verboseLabel": "SRAX, Inc [Member]" } } }, "localname": "SRAXIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SauerEnergyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sauer Energy Inc Member", "terseLabel": "Sauer Energy, Inc. [Member]" } } }, "localname": "SauerEnergyIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_ScheduleOfAmountsOfRevenueAndEarningsOfMangoMoiAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Amounts Of Revenue And Earnings Of Mango Moi Abstract" } } }, "localname": "ScheduleOfAmountsOfRevenueAndEarningsOfMangoMoiAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfCondensedConsolidatedResultsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Consolidated Results Of Operations Abstract" } } }, "localname": "ScheduleOfCondensedConsolidatedResultsOfOperationsAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Such Assets And Liabilities Abstract" } } }, "localname": "ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement Member", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ShareholderEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Line Items]" } } }, "localname": "ShareholderEquityDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Table]" } } }, "localname": "ShareholderEquityDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Abstract]" } } }, "localname": "ShareholderEquityLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Table]" } } }, "localname": "ShareholderEquityTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderOwningPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Owning Preferred Stock", "terseLabel": "Shareholder owning preferred stock" } } }, "localname": "ShareholderOwningPreferredStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesCancelable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares cancelable.", "label": "Shares Cancelable", "terseLabel": "Shares cancellable" } } }, "localname": "SharesCancelable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_SharesCancelableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Cancelable Member", "terseLabel": "Shares Cancellable" } } }, "localname": "SharesCancelableMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "bfyw_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Of Common Stock", "terseLabel": "Shares of common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Of Restricted Common Stock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "SharesOfRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StephenLetourneauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stephen Letourneau Member", "terseLabel": "Stephen Letourneau [Member]" } } }, "localname": "StephenLetourneauMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_StockIssuedDuringPeriodShareNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Share New Issues", "terseLabel": "Series A preferred stock were issued" } } }, "localname": "StockIssuedDuringPeriodShareNewIssues", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares canceled and returned to the Company.", "label": "Stock Issued During Period Shares Common Shares Canceled And Returned To The Companyin Shares", "terseLabel": "Common shares cancelled and returned to the Company (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares issued for shares payable.", "label": "Stock Issued During Period Shares Common Shares Issued For Shares Payablein Shares", "terseLabel": "Common shares issued for shares payable (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period common shares canceled and returned to the Company.", "label": "Stock Issued During Period Value Common Shares Canceled And Returned To The Company", "terseLabel": "Common shares cancelled and returned to the Company" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in common shares issued for shares payable.", "label": "Stock Issued During Period Value Common Shares Issued For Shares Payable", "terseLabel": "Common shares issued for shares payable" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodValueWarrantsIssued1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of warrants issued.", "label": "Stock Issued During Period Value Warrants Issued1", "terseLabel": "Warrants Issued" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsIssued1", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option description.", "label": "Stock Option Description", "terseLabel": "Stock option, description" } } }, "localname": "StockOptionDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock price description.", "label": "Stock Price Description", "terseLabel": "Stock price description" } } }, "localname": "StockPriceDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Purchase Warrant Liability [Abstract]" } } }, "localname": "StockPurchaseWarrantLiabilityAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase warrant liability description.", "label": "Stock Purchase Warrant Liability Description", "terseLabel": "Stock purchase warrant liability description" } } }, "localname": "StockPurchaseWarrantLiabilityDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Purchase Warrant Liability Text Block", "terseLabel": "Stock Purchase Warrant Liability" } } }, "localname": "StockPurchaseWarrantLiabilityTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability" ], "xbrltype": "textBlockItemType" }, "bfyw_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_TotalPaymentsConsideredContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total payments considered contributions.", "label": "Total Payments Considered Contributions", "terseLabel": "Total payments considered contributions (in Dollars)" } } }, "localname": "TotalPaymentsConsideredContributions", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_TotalUnamortizedStockOptionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total unamortized stock option expense.", "label": "Total Unamortized Stock Option Expense", "terseLabel": "Total unamortized stock option expense (in Dollars)" } } }, "localname": "TotalUnamortizedStockOptionExpense", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_WarrantCoverageRaisedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant coverage amount raised.", "label": "Warrant Coverage Raised Percentage", "terseLabel": "Warrant coverage raised percentage" } } }, "localname": "WarrantCoverageRaisedPercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bfyw_WilliamsburgVentureHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Williamsburg Venture Holdings LLCMember", "terseLabel": "Williamsburg Venture Holdings LLC [Member]" } } }, "localname": "WilliamsburgVentureHoldingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_YapoMbeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Yapo Mbe Member", "terseLabel": "Yapo M\u2019be [Member]" } } }, "localname": "YapoMbeMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r137", "r266", "r267", "r270", "r271", "r292", "r322", "r324", "r372", "r375", "r376", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r137", "r266", "r267", "r270", "r271", "r292", "r322", "r324", "r372", "r375", "r376", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r360", "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Schedule of condensed consolidated results of operations" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r365", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in capita (in Dollars)" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r243", "r244", "r245", "r361", "r362", "r363", "r381" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "verboseLabel": "Additional Paid-in-Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r59", "r61", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrants Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock option expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Share-based expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r26", "r36", "r88", "r216" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortized debt discount and debt issuance costs" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r100", "r116", "r135", "r169", "r172", "r176", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r266", "r270", "r276", "r343", "r373", "r374", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r112", "r121", "r135", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r266", "r270", "r276", "r343", "r373", "r374", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Significant Accounting Policies and Use of Estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r263", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r72", "r73", "r263", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Loss per share (in Dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.", "label": "Business Acquisitions, Purchase Price Allocation, Subsequent Years, Remaining Adjustments", "terseLabel": "Purchase price" } } }, "localname": "BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Paid consideration (in Dollars)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r80", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Sales Tax Payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r74", "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r74", "r75" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Owning, percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r114", "r325" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r32", "r38", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Ending cash balance", "periodStartLabel": "Beginning cash balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r32", "r86" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON-CASH FINANCING TRANSACTIONS:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r117", "r118", "r119", "r135", "r153", "r154", "r156", "r158", "r161", "r162", "r181", "r192", "r194", "r195", "r196", "r199", "r200", "r218", "r219", "r221", "r225", "r231", "r276", "r323", "r349", "r357", "r364" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r58", "r190", "r191", "r319", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r361", "r362", "r381" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "netLabel": "Common Stock [Member]", "terseLabel": "Shares", "verboseLabel": "Common" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common shares, outstanding", "verboseLabel": "Common stock value (in Shares)" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Shares of common stock" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042 issued and outstanding as of May 31, 2022 and February 28, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r82", "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r40", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Purchase agreement description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Note Payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r18" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes payable, net accumulated interest" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r22", "r135", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r276", "r373" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r93", "r94", "r99", "r137", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r284", "r334", "r335", "r336", "r337", "r338", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPriceIncrease": { "auth_ref": [ "r210", "r232" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision.", "label": "Debt Instrument, Convertible, Conversion Price, Increase", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Debt Forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r89", "r90", "r201", "r284", "r335", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r17", "r89", "r213" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Bears interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r17", "r89", "r217", "r284" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r122", "r334", "r382" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r18", "r137", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r284", "r334", "r335", "r336", "r337", "r338", "r358" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r18" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal amount", "verboseLabel": "Principal amount (in Dollars)" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Outstanding shares percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Purchase price", "verboseLabel": "Purchase price (in Dollars)" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r88", "r90", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Discount amount", "verboseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r88", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "terseLabel": "Discount amount (in Dollars)" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r67", "r68" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current", "terseLabel": "Deferred Compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r36", "r56" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r130", "r143", "r144", "r145", "r146", "r147", "r151", "r153", "r156", "r157", "r158", "r159", "r274", "r275", "r310", "r313", "r330" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per common share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r130", "r143", "r144", "r145", "r146", "r147", "r153", "r156", "r157", "r158", "r159", "r274", "r275", "r310", "r313", "r330" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r61", "r110", "r126", "r127", "r128", "r138", "r139", "r140", "r142", "r148", "r150", "r160", "r182", "r233", "r243", "r244", "r245", "r256", "r257", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares of common stock" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r36", "r60" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Interest expense" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r115", "r183", "r309", "r333", "r343", "r369", "r370" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r185", "r188", "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r36", "r184", "r186", "r189", "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment expense" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "terseLabel": "Goodwill" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r21", "r135", "r169", "r171", "r175", "r177", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r276", "r332", "r373" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r136", "r250", "r251", "r254", "r258", "r259", "r260", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r125", "r248", "r249", "r251", "r252", "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred Compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r356" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntercompanyAgreementsDescription": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.", "label": "Intercompany Agreements, Description", "terseLabel": "Independent director agreements, description" } } }, "localname": "IntercompanyAgreementsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "terseLabel": "Associated expenses" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r120", "r326", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r135", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r267", "r270", "r271", "r276", "r331", "r373", "r386", "r387" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r95", "r103", "r343", "r359", "r368", "r383" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r113", "r135", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r267", "r270", "r271", "r276", "r343", "r373", "r386", "r387" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoanProcessingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.", "label": "Loan Processing Fee", "terseLabel": "Paid expenses" } } }, "localname": "LoanProcessingFee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r4", "r94", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Loan Amount" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Shareholders [Member]" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturityOfTimeDeposits": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of customer deposits, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity of Time Deposits", "terseLabel": "Registration rights expires" } } }, "localname": "MaturityOfTimeDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r34", "r37" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r37", "r96", "r105", "r111", "r123", "r124", "r128", "r135", "r141", "r143", "r144", "r145", "r146", "r149", "r150", "r155", "r169", "r171", "r175", "r177", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r275", "r276", "r332", "r373" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAllocatedToGeneralPartners": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of net income allocated to general partners.", "label": "Net Income (Loss) Allocated to General Partners", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossAllocatedToGeneralPartners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofamountsofrevenueandearningsofmangomoiTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r81", "r233", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r25" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankNoncurrent": { "auth_ref": [ "r4", "r94", "r101" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Notes Payable to Bank, Noncurrent", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "NotesPayableToBankNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r169", "r171", "r175", "r177", "r332" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Income/(Loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r83" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Other Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "OtherCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r24", "r107" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other expense", "terseLabel": "Paid expenses (in Dollars)" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r106" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r18" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Noncurrent", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Current", "terseLabel": "Related Party Notes Payable" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "terseLabel": "Amount paid", "verboseLabel": "Agreement fees" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r31" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance Cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r27" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Fixed Asset" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares", "verboseLabel": "Series A" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r218" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r218" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r5", "r62" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r353" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaids and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification of Prior Year Presentation" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r29" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Convertible loan, net of original issue discount" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds total (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds from (Repayments of) Notes Payable", "terseLabel": "Notes Payable \u2013 LT" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Noncontrolling interest" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r111", "r123", "r124", "r131", "r135", "r141", "r149", "r150", "r169", "r171", "r175", "r177", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r265", "r268", "r269", "r275", "r276", "r311", "r332", "r341", "r342", "r354", "r373" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income/(loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r104", "r312", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r234", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r109", "r288", "r289", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r234", "r288", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r286", "r287", "r289", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherShortTermDebt": { "auth_ref": [ "r30" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.", "label": "Repayments of Other Short-Term Debt", "negatedLabel": "Proceed from related party note payable" } } }, "localname": "RepaymentsOfOtherShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r63", "r102", "r317", "r318", "r343" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r138", "r139", "r140", "r142", "r148", "r150", "r182", "r243", "r244", "r245", "r256", "r257", "r273", "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r129", "r135", "r167", "r168", "r170", "r173", "r174", "r178", "r179", "r180", "r181", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r276", "r311", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofamountsofrevenueandearningsofmangomoiTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesNetOfInterestExpense": { "auth_ref": [ "r167", "r168", "r170", "r173", "r174", "r178", "r179", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues, Net of Interest Expense", "terseLabel": "Total revenues" } } }, "localname": "RevenuesNetOfInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "terseLabel": "Annual salary of payable" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of fair value of such assets and liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r50", "r51", "r52", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of amounts of revenue and earnings of mango moi" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r351", "r352", "r378" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share based expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Grant option exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock option outstanding intrinsic value (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r235", "r237", "r238", "r239", "r240", "r241", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option expire term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options fair value the grant date (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Transfer of shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Exercise price per shares (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances (in Shares)", "periodStartLabel": "Balances (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Short-Term Debt, Interest Rate Increase", "terseLabel": "Interest rate" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermNonBankLoansAndNotesPayable": { "auth_ref": [ "r12" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.", "label": "Short-Term Non-bank Loans and Notes Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "ShortTermNonBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r44", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r117", "r118", "r119", "r135", "r153", "r154", "r156", "r158", "r161", "r162", "r181", "r192", "r194", "r195", "r196", "r199", "r200", "r218", "r219", "r221", "r225", "r231", "r276", "r323", "r349", "r357", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r61", "r110", "r126", "r127", "r128", "r138", "r139", "r140", "r142", "r148", "r150", "r160", "r182", "r233", "r243", "r244", "r245", "r256", "r257", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r138", "r139", "r140", "r160", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r40", "r41", "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Warrants issued and extended for common stock issuance costs" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r5", "r6", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Series A preferred shares issued after reorganization (in Shares)", "verboseLabel": "Commitment shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common shares issued for services to Company (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r61", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued after reorganization (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r61", "r63" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r19", "r61", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Series A preferred shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common shares issued for services to Company", "verboseLabel": "Purchase price" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Common shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "The total stock option expense (in Dollars)" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r53", "r343", "r359", "r368", "r383" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r66", "r134", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r233", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r283", "r294" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r283", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r283", "r294" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r293", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r40", "r41", "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Purchase price of stock" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Table Text Block Supplement [Abstract]" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockPreferredShares": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Preferred, Shares", "terseLabel": "Purchase common shares (in Shares)" } } }, "localname": "TreasuryStockPreferredShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r47", "r48", "r49", "r163", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r152", "r158" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r151", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding - Basic (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Industry Guide", "Number": "3", "Paragraph": "D-E", "Publisher": "SEC", "Section": "V", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r345": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r346": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r347": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r348": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 53 0001213900-23-020741-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-020741-xbrl.zip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Ð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�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